Synthetic Datasets for Autonomous Driving: A Survey

Autonomous driving techniques have been flourishing in recent years while thirsting for huge amounts of high-quality data. However, it is difficult for real-world datasets to keep up with the pace of changing requirements due to their expensive and time-consuming experimental and labeling costs. Therefore, more and more researchers are turning to synthetic datasets to easily generate rich and changeable data as an effective complement to the real world and to improve the performance of algorithms. In this paper, we summarize the evolution of synthetic dataset generation methods and review the work to date in synthetic datasets related to single and multi-task categories for to autonomous driving study. We also discuss the role that synthetic dataset plays the evaluation, gap test, and positive effect in autonomous driving related algorithm testing, especially on trustworthiness and safety aspects. Finally, we discuss general trends and possible development directions. To the best of our knowledge, this is the first survey focusing on the application of synthetic datasets in autonomous driving. This survey also raises awareness of the problems of real-world deployment of autonomous driving technology and provides researchers with a possible solution.Comment: 19 pages, 5 figure

Research Progress of Chimeric Antigen Receptor NK Cells in Treatment of Lymphoma

Adoptive cell immunotherapy has been a hot spot in tumor research in recent years. Chimeric antigen receptor T cells (CAR-T) have achieved great success in hematological tumors and have changed the current tumor treatment landscape to a certain extent. However, the application of CAR-T therapy in clinics is limited due to its serious side effects and high treatment costs. Natural killer (NK) cells are important immune cells in the body and have native cytotoxicity and well safety. NK cells based on CAR engineering (CAR-NK) have shown powerful anti-tumor activity and safety in preclinical research and could be the next generation of CAR platform-based cellular immunotherapy. This review will systematically introduce the current research status of CAR-NK cells in lymphoma